CD30-positive
Showing 1 - 25 of >10,000
A Study of People With CD30 Positive Lymphoma in China
Not yet recruiting
- Lymphoma
- (no location specified)
Aug 17, 2022
Brentuximab Vedotin Intravenous Infusion "Untreated
Active, not recruiting
- Untreated CD30-Positive Hodgkin's Lymphoma
- Brentuximab vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Mar 24, 2022
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)
Recruiting
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Classical Hodgkin Lymphoma
- CD30.CAR-EBVST cells
-
Houston, Texas
- +1 more
Jul 20, 2022
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Oct 11, 2022
T-Cell Lymphoma Trial (Brentuximab vedotin)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- (no location specified)
Jun 30, 2022
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
-
Duarte, California
- +3 more
Jul 21, 2022
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)
Not yet recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- Peripheral T Cell Lymphoma
- AFM13
- +4 more
- (no location specified)
May 30, 2023
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)
Withdrawn
- T Cell Lymphoma
- Brentuximab Vedotin
-
Kansas City, KansasThe University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023
Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)
Not yet recruiting
- Lymphoma
- Brentuximab Vedotin
- +3 more
-
Beijing, China
- +15 more
Jan 4, 2023
Brentuximab Vedotin in Pediatric Hodgkin Lymphoma
Not yet recruiting
- Hodgkin Lymphoma
- Brentuximab Vedotin
- (no location specified)
Jul 28, 2022
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker
Recruiting
- CD30-Positive Neoplastic Cells Present
- Malignant Mesothelioma
- Brentuximab Vedotin
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Jan 3, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +9 more
- Anti-CD30/CD16A Monoclonal Antibody AFM13
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- Pembrolizumab
- (no location specified)
Jul 22, 2022
NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)
Not yet recruiting
- NK/T Cell Lymphoma Nos
- Brentuximab Vedotin in Combination with Tislelizumab
- (no location specified)
Apr 6, 2022
Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)
Completed
- Lymphatic Diseases
- Brentuximab Vedotin
-
Bologna, Italy
- +3 more
Mar 21, 2022
Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)
Terminated
- Leukemia
- Brentuximab Vedotin
- 5-Azacytidine
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 7, 2022
CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive DLBCL, CD30-Positive Gray Zone Lymphoma Trial in
Completed
- CD30 Positive Primary Mediastinal Large B-cell Lymphoma
- +2 more
- brentuximab vedotin
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Dec 14, 2020
Germ Cell Tumor Trial in Minneapolis (Brentuximab Vedotin, Bevacizumab)
Terminated
- Germ Cell Tumor
- Brentuximab Vedotin
- Bevacizumab
-
Minneapolis, MinnesotaUniversity of Minnesota
Nov 12, 2020
Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic Trial in China (Brentuximab Vedotin)
Completed
- Hodgkin Disease
- Lymphoma, Large-Cell, Anaplastic
- Brentuximab Vedotin
-
Beijing, Beijing, China
- +6 more
Feb 3, 2021
DLBCL Trial in Rotterdam (R-DHAP, Brentuximab Vedotin)
Recruiting
- DLBCL
- R-DHAP
- Brentuximab Vedotin
-
Rotterdam, NetherlandsNL-Rotterdam-ERASMUSMC
Dec 9, 2020
Brentuximab Vedotin in Adults With CD30-positive Lymphoma
Recruiting
- Lymphoma
- No Intervention
-
Hefei, Anhui, China
- +25 more
Jul 14, 2022
Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Chemotherapy
- Cell infusion
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Oct 13, 2023
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)
Recruiting
- Germ Cell Tumor
- Nonseminomatous Germ Cell Tumor
- ATLCAR.CD30 Cells
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)
Not yet recruiting
- Classical Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- GEN3017
- (no location specified)
Aug 25, 2023